Search the Community
Showing results for tags 'myocarditis'.
Found 1 result
Cantargia Selects CAN10 as Development Project in Systemic Sclerosis and Myocarditis. Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP) and the project will focus on unmet medical need in systemic sclerosis and myocarditis. PR Newswire, 12/05/2019. (Also see Interleukins) This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.